Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
| Descriptor ID |
D017430
|
| MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
|
| Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 2 | 1 | 3 |
| 1996 | 3 | 1 | 4 |
| 1997 | 2 | 1 | 3 |
| 1998 | 3 | 1 | 4 |
| 1999 | 3 | 3 | 6 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 2 | 3 |
| 2003 | 1 | 3 | 4 |
| 2004 | 2 | 8 | 10 |
| 2005 | 4 | 3 | 7 |
| 2006 | 1 | 5 | 6 |
| 2007 | 3 | 10 | 13 |
| 2008 | 4 | 4 | 8 |
| 2009 | 3 | 7 | 10 |
| 2010 | 5 | 6 | 11 |
| 2011 | 2 | 2 | 4 |
| 2012 | 4 | 7 | 11 |
| 2013 | 5 | 5 | 10 |
| 2014 | 5 | 7 | 12 |
| 2015 | 6 | 6 | 12 |
| 2016 | 5 | 11 | 16 |
| 2017 | 3 | 14 | 17 |
| 2018 | 4 | 10 | 14 |
| 2019 | 5 | 4 | 9 |
| 2020 | 3 | 9 | 12 |
| 2021 | 1 | 5 | 6 |
| 2022 | 4 | 10 | 14 |
| 2023 | 3 | 7 | 10 |
| 2024 | 2 | 4 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.
-
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. J Clin Oncol. 2024 Nov 10; 42(32):3806-3816.
-
Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men. Cancer. 2024 Oct 01; 130(19):3305-3310.
-
Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Cancer Med. 2024 Jun; 13(12):e7334.
-
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123.
-
Magnetic resonance imaging-ultrasound fusion guided focal cryoablation for men with intermediate-risk prostate cancer. Urol Oncol. 2024 May; 42(5):158.e1-158.e10.
-
Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2024 Jan 04; 161(1):1-3.
-
National Long-term Survival Estimates After Radical Prostatectomy for Prostate Cancer. Urology. 2024 02; 184:135-141.
-
The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer. J Natl Cancer Inst. 2023 11 08; 115(11):1364-1373.
-
Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system. Cancer. 2023 10 15; 129(20):3326-3333.
-
Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial. J Urol. 2023 10; 210(4):630-638.